I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Long-term tolerability and efficacy after initial PegIFN-al..:
Flygt, Hjalmar
;
Söderlund, Stina
;
Stentoft, Jesper
...
10.1111/ejh.13699. , 2022
Link:
http://hdl.handle.net/10138/339626
RT Journal T1
Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
UL https://suche.suub.uni-bremen.de/peid=base-ftunivhelsihelda:oai:helda.helsinki.fi:10138_339626&Exemplar=1&LAN=DE A1 Flygt, Hjalmar A1 Söderlund, Stina A1 Stentoft, Jesper A1 Richter, Johan A1 Koskenvesa, Perttu A1 Mustjoki, Satu A1 Majeed, Waleed A1 Lubking, Anna A1 Dreimane, Arta A1 Markevarn, Berit A1 Stenke, Leif A1 Myhr Eriksson, Kristina A1 Gjertsen, Bjorn Tore A1 Gedde-Dahl, Tobias A1 Dimitrijevic, Andreja A1 Udby, Lene A1 Olsson-Stromberg, Ulla A1 Hjorth-Hansen, Henrik PB Wiley YR 2022 K1 BCR-ABL Positive K1 chronic myelogenous leukemia K1 clinical trial K1 dasatinib K1 interferon-alpha K1 CHRONIC MYELOID-LEUKEMIA K1 TREATMENT-FREE REMISSION K1 MOLECULAR RESPONSE K1 FRONTLINE NILOTINIB K1 IMATINIB K1 COMBINATION K1 INTERFERON-ALPHA-2B K1 SURVIVAL K1 PHASE-2 K1 TRIAL K1 Cancers JF 10.1111/ejh.13699 LK http://hdl.handle.net/10138/339626 DO http://hdl.handle.net/10138/339626 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)